Is Lineage Cell Therapeutics Inc (LCTX) a Stock to Watch After Gaining 13.68% This Week?

The market has been high on Lineage Cell Therapeutics Inc (LCTX) stock recently. LCTX gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Lineage Cell Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on LCTX!

See Full LCTX Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With LCTX Stock Today?

Lineage Cell Therapeutics Inc (LCTX) stock is higher by 10.83% while the S&P 500 is down -0.47% as of 10:19 AM on Thursday, Oct 5. LCTX has gained $0.13 from the previous closing price of $1.22 on volume of 157,294 shares. Over the past year the S&P 500 has gained 11.95% while LCTX has gained 9.02%. LCTX lost -$0.13 per share in the over the last 12 months.

More About Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for acute spinal cord injuries and VAC2, a allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer. Its lead cell delivery clinical program is Renevia, an investigational medical device developed as an alternative for whole adipose tissue transfer procedures. Click Here to get the full Stock Report for Lineage Cell Therapeutics Inc stock.